C. elegans serves as a valuable tool for biological and basic medical research, with the advantages of ease of manipulation at the laboratory level, genetic tractability, and a well-defined developmental pedigree. Besides, thanks to its great homology with human genes, the worm is an exceptional model for genetic and molecular analysis of human disease-related genes. At present, C. elegans has been widely exploited for the identification and functional analysis of drugs in vivo, including the anti-cancer agent. At CD BioSciences, we specialize in providing high quality services in the field of C. elegans research. With a proven phenotype-based high-throughput screening platform and sophisticated equipment, we are proud to offer you anticancer drug screening services.

C. elegans as a Model for Anti-cancer Drug Screening

C. elegans serves as an ideal model system for high-throughput drug screening in living animals with the advantages of body transparency, short lifespan, completed whole genome sequencing, and the ability to mimic all aspects of mammalian disease.

Signaling pathways (including oncogenic signaling pathways, such as Notch, Wnt, and Ras) and their regulators in C. elegans are highly conserved in most vertebrates, including humans. Since aberrant control of these signaling pathways can lead to either over proliferation of a specific cell type or loss of germline stem cells, resulting in sterility. Therefore, the sterility phenotype of C. elegans facilitates an available strategy for screening anti-cancer agents that modulate the oncogenic signaling pathways directly or indirectly.

Fig.1 Notch signaling pathways and a strategy for the phenotype-based drug identification using C. elegans mutants. (Kobet R A, et al., 2014)

Our Services

As a leading global provider of customized services focused on C. elegans research, CD BioSciences has experienced researchers and scientists who are confident in providing you with high quality anticancer drug screening services. Here we provide C. elegans Notch mutants, Wnt mutants and Ras mutants for the identification of drugs that may target the conserved oncogenic signaling pathways positively or negatively. The C. elegans mutants we offer for drug screening include, but are not limited to:

Our Advantages

CD BioSciences is dedicated to providing high-quality service to accelerate and improve our clients' research outcomes. We provide a phenotype-based high-throughput screening system combing advanced automated instruments for identifying anti-cancer drugs that may target oncogenic signaling pathways. If you are interested in our service, please feel free to contact us for more details.

Reference

1. Kobet R A, Pan X, Zhang B, et al. Caenorhabditis elegans: A model system for anti-cancer drug discovery and therapeutic target identification[J]. Biomolecules & therapeutics, 2014, 22(5): 371.

Related Services

• Probiotics Screening Service
• Neurological Disease Drug Screening Service
• Anti-infective Compound Screening Service
• Pro-longevity Compound Screening Service